9製品基本Q&A https://www.msdconnect.jp/products/gardasil-silgard9/info/faq-silgard9/(最終アクセス2022年5月8日)
2)Castellsaguè X, et al : End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV(types 6, 11, 16, 18)recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105 : 28-37, 2011
3)Azuma Y, et al : Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2/3 and invasive cervical cancer in Japanese women. Jpn J Clin Oncol 44 : 910-917, 2014
4)Sakamoto J, et al : Single type infection of human papillomavirus as a cause for high-grade cervical intraepithelial neoplasia and invasive cancer in Japan. Papillomavirus Res 6 : 46-51, 2018
5)Onuki M, et al : Human papillomavirus infections among Japanese women : age-related prevalence and type-specific risk for cervical cancer. Cancer Sci 100 : 1312-1316, 2009
6)Matsumoto K, et al : Monitoring the impact of a national HPV vaccination program in Japan(MINT Study) : rationale, design and methods. Jpn J Clin Oncol 44 : 1000-1003, 2014
7)Onuki M, et al : Human papillomavirus genotype contribution to cervical cancer and precancer : Implications for screening and vaccination in Japan. Cancer Sci 111 : 2546-2557, 2020
8)Lei J, et al : HPV vaccination and the risk of invasive cervical cancer. N Engl J Med 383 : 1340-1348, 2020
9)Kjaer S, et al : Real-world effectiveness of human papillomavirus vaccination against cervical cancer. J Natl Cancer Inst 113 : 1329-1335, 2021
10)Onuki M, et al : Human papillomavirus vaccine effectiveness by age at first vaccination among Japanese women. Cancer Sci 113 : 1428-1434, 2022
11)北村邦夫 : 結婚しない,セックスしない若者たち―「第8回男女の生活と意識に関する調査結果」結果から.JASE現代性教育研究ジャーナル72 : 1-10, 2017
12)Combita AL, et al : Reduction in vaccine HPV type infections in a young women group(18-25 years)five years after HPV vaccine introduction in Colombia. Cancer Prev Res(Phila) 15 : 55-66, 2021